Please login to the form below
Dermavant
This page shows the latest Dermavant news and features for those working in and with pharma, biotech and healthcare.
Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
Dermavant Sciences, a biopharmaceutical company specialising in immuno-dermatology, has shared new data assessing Vtama (tapinarof) 1% cream for the treatment of plaque psoriasis in adults. ... In May, Dermavant announced that the US Food and Drug
Latest news
-
Dermavant’s Vtama receives FDA approval for plaque psoriasis
Dermavant Sciences’ Vtama (tapinarof) has been approved by the US Food and Drug Administration (FDA) to treat plaque psoriasis in adults. ... Todd Zavodnick, CEO of Dermavant, said: “We are delighted with our FDA-approved label for Vtama cream, which
-
Urovant slips on phase 3 incontinence drug data
Others cued up for results include phase 3 trials of Myovant’s relugolix in uterine fibroids, endometriosis and prostate cancer, and Dermavant’s tapinarof in psoriasis.
-
GSK sells eczema and psoriasis drug to Dermavant for £250m
Psoriasis and atopic dermatitis (eczema) candidate tapinarof is being transferred to Roivant Sciences group company Dermavant in return for £150m upfront and another £100m in the offing if it meets development
-
Roivant gets $1.1bn investment from Japan's SoftBank
Roivant - the holding company for subsidiaries Axovant, Myovant, Dermavant, Enzyvant and just-launched urology specialist Urovant - said the cash injection will be used to launch new subsidiaries "within and beyond the
More from news
Approximately 3 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Dermavant strengthens executive team
Dermavant Sciences, a biopharmaceutical company focused on delivering therapies for dermatologic conditions, has bolstered its executive team with the addition of four new hires. ... Peterson, who previously worked at Sienna Biopharmaceuticals as its
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- The patient voice – the value of patient-reported outcomes in HTA
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Strategic commitment
- Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
- AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug
- NHS England launches hepatitis C screening scheme to reach 2030 elimination goal
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Valneva and Pfizer initiate phase 3 Lyme disease vaccine study
- GSK’s ViiV and Medicines Patent Pool agree deal for HIV prevention
- GSK/Merck KGgA cancer drug fails in third trial
- Chiesi Group's Trimbow wins European licence
- Roche shares new positive Ocrevus data for MS patients
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Using behavioural psychology to improve patient recruitment
PMHub
Impetus Digital
Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...
Latest intelligence
- Strategic commitment
- ...
- KOL Ambassador Program & Podcast Creation: A Customer Story
- ...
- Animation: Living With
- The journey from the patient's perspective...
